Previous Close | 4.8500 |
Open | 4.8800 |
Bid | 4.9400 x 200 |
Ask | 5.0300 x 100 |
Day's Range | 4.8450 - 4.9900 |
52 Week Range | 1.6300 - 5.7000 |
Volume | |
Avg. Volume | 818,386 |
Market Cap | 687.977M |
Beta (5Y Monthly) | 0.77 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3300 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.79 |
AUSTIN, Texas, March 22, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
LANGHORNE, Pa., March 07, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2023 and provided a business update.
LANGHORNE, Pa., March 06, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024 at 5:00am PT/8:00am ET. A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.